Skip to content

Nuvalent, Inc. NUVL Accrued Expenses

Accrued Expenses at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$7.07M+60.9%
Exelixis logo
ExelixisEXEL
$100.29M-20.1%
Incyte logo
IncyteINCY
$124.92M+21.5%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$1.02B-3.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s accrued expenses?
Nuvalent, Inc. (NUVL) reported accrued expenses of $58.92M in Q1 2026.
How has Nuvalent, Inc.'s accrued expenses changed year-over-year?
Nuvalent, Inc.'s accrued expenses increased by 20.6% year-over-year, from $48.87M to $58.92M.
What is the long-term trend for Nuvalent, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s accrued expenses has grown at a 120.5% compound annual growth rate (CAGR), from $1.17M to $61.01M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.